Biotechnology
AstraZeneca discontinues Phase 3 trial of volrustomig, its PD-1/CTLA-4 bispecific antibody in lung cancer, revealing structural challenges in displacing Keytruda and diverging fortunes in the bispecific antibody race.
Biotechnology
Epicrispr's EPI-321 produced measurable muscle growth in FSHD patients with a single dose, without altering DNA. The $90M Series C and early clinical data mark a potential inflection point for epigenetic medicine.
Biotechnology
Definium Therapeutics' Phase 3 Voyage trial shows DT120, a pharmaceutically optimized LSD formulation, achieved an 11.6-point reduction in anxiety scores—the strongest placebo-adjusted efficacy benefit ever observed in a pivotal GAD study.
Pharmaceuticals
Eli Lilly filed six lawsuits against black-market sellers of retatrutide on August 12, 2026. The legal action reveals a deeper structural tension in the obesity drug market that litigation alone cannot resolve.
Policy
Trump's executive order to reduce childhood vaccines from 17 to 11 raises critical questions about public health policy, pharmaceutical industry impacts, and the politicization of vaccine recommendations.
Biotechnology
Silence Therapeutics' Phase 2 SANRECO trial shows divesiran achieved an 88% clinical response rate in polycythemia vera patients, with quarterly dosing that could transform disease management for this rare blood disorder.
Wall Street Wire
Ten of the most followed names in biotech investing funded Entera Bio two weeks ago through its pivotal trial of EB613. Understanding the potential these investors see in Entera requires understanding the Company’s lead asset and how it could transform the way osteoporosis patients are treated.
Policy
Senators Pete Ricketts and Elissa Slotkin have introduced the Biotech Investment National Security Act (BINSA), which would subject US-China pharmaceutical deals to federal scrutiny. The bipartisan bill signals a major shift in how Washington views biotech collaboration with China.
Wall Street Wire
Medication errors cost the world an estimated $42 billion a year. Seegnal is tackling the problem with a smarter, patient-specific alert system already used by roughly 15,000 clinicians—and now the company is testing its approach in the U.S.
Get our in depth reports sent directly to your inbox. Unsubscribe anytime.
The FDA's approval of Orzeyful marks the first medicine to treat narcolepsy type 1 by directly restoring orexin signaling, representing a paradigm shift from symptom management to mechanism correction.
LifeMine Therapeutics raised $263 million to develop LIFE-001, a next-generation calcineurin inhibitor designed to prevent organ rejection without the kidney damage caused by current immunosuppressants.
Today is the PDUFA decision date for Moderna's mFlusiva, the first mRNA-based seasonal flu vaccine ever to seek US approval. A unanimous 9-0 advisory panel vote, a 27% efficacy advantage over standard flu shots, and a dramatic regulatory reversal set the stage for a landmark decision.
Novartis receives FDA approval for Pluvicto in metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient population and validating radioligand therapy's role earlier in the treatment journey.
Novo Nordisk's ZEUS trial failure reveals a critical gap in cardiovascular drug development: reducing inflammation doesn't guarantee clinical benefit. What this means for the future of anti-inflammatory therapies.
On July 30, 2026, an FDA advisory panel voted 10-3 in favor of Replimune's RP1, an oncolytic virus therapy for advanced melanoma. The vote represents a potential turning point after two prior rejections and signals a possible shift in the FDA's approach to single-arm trials in oncology.
Altimmune's pemvidutide just posted positive Phase 2 data in alcohol use disorder. The result is more than a single trial win. It is the latest signal that GLP-1 biology is expanding into addiction medicine in ways the field is only beginning to understand.
argenx's $2.2 billion acquisition of Forte Biosciences is more than an immunology M&A deal. It is a strategic bet on CD122 biology and a mechanism that targets the T-cell and NK-cell axis in ways the company's existing portfolio does not.
Eli Lilly's positive Phase 3 results for retatrutide show 22.6% average weight loss in patients with severe obesity and cardiovascular disease—a level historically associated with bariatric surgery. What the data mean for the future of obesity medicine.
The FDA's approval of Lytenava formalizes what retina specialists have done off-label for over 20 years. The regulatory hurdle is cleared. The commercial one may prove harder.
Centanafadine's FDA decision on July 24, 2026 marks a potential breakthrough in ADHD treatment. As the first triple monoamine reuptake inhibitor, it could offer a new option for patients who cannot tolerate stimulants.
GSK's FDA approval of Jideytro marks more than a drug launch—it signals the arrival of second-generation targeted therapies in oncology with meaningful clinical advantages over first-generation inhibitors.
